Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LENZ Therapeutics, Inc. (LENZ)
USD4.85
-0.08 (-1.62%)
US NASDAQ Healthcare Biotechnology
Address
445 Marine View Avenue 92014
Solana Beach, CA, US
Solana Beach, CA, US
CEO
Evert Schimmelpennink
Website
lenz-tx.com
IPO
2024-03-22
CIK 1815776 ISIN US52635N1037
Also trades on
NASDAQ Global Market · GRPH (USD)
NASDAQ Global Select · LENZ (USD)
Description
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.85
-0.08 (-1.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
785.3K
Beta
1.62
Float Shares
27.72M
Free Float %
88.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -20.82% | -19.37% | -17.86% | -38.59% | -70.14% | -50.56% | -72.69% | -47.27% | -90.97% | -90.97% | -90.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
4.85
Low
12.00
+147.4%
Consensus
12.00
+147.4%
Median
12.00
+147.4%
High
12.00
+147.4%
DCF (Unlevered)
2.46
-49.2%
DCF (Levered)
1.08
-77.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
61.50
+1,168.0%
|
| All Time | 5 |
48.40
+897.9%
|
Quality scores
Altman Z-Score
5.57
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-21.8% Q1'26: -149.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-464.6% Q1'26: -1,767.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-477.5% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+35.4% Q1'26: +13.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 5.00M (-100.0%)
|
19.09M
est: 19.51M (-2.2%)
|
23.91M
18.73M – 29.48M
+22.5% YoY
|
76.02M
55.10M – 89.76M
+218.0% YoY
|
154.76M
153.26M – 156.26M
+103.6% YoY
|
277.71M
198.87M – 361.43M
+79.4% YoY
|
368.21M
263.69M – 479.23M
+32.6% YoY
|
| EBITDA |
-49.71M
est: 1.30M (-3,919.0%)
|
-91.14M
est: 5.08M (-1,894.2%)
|
6.22M
4.88M – 7.67M
+22.5% YoY
|
19.79M
14.34M – 23.37M
+218.0% YoY
|
40.29M
39.90M – 40.68M
+103.6% YoY
|
72.30M
51.77M – 94.09M
+79.4% YoY
|
95.86M
68.65M – 124.76M
+32.6% YoY
|
| EBIT |
-49.77M
est: 1.30M (-3,925.0%)
|
-91.14M
est: 5.08M (-1,894.9%)
|
6.22M
4.87M – 7.67M
+22.5% YoY
|
19.78M
14.34M – 23.36M
+218.0% YoY
|
40.27M
39.88M – 40.66M
+103.6% YoY
|
72.27M
51.75M – 94.05M
+79.4% YoY
|
95.82M
68.62M – 124.71M
+32.6% YoY
|
| Net Income |
-49.77M
est: -75.88M (+34.4%)
|
-82.13M
est: -72.01M (-14.1%)
|
-125.66M
-143.01M – -86.10M
-74.5% YoY
|
-96.50M
-96.57M – -66.60M
+23.2% YoY
|
-22.50M
-56.04M – 27.71M
+76.7% YoY
|
51.36M
32.41M – 71.49M
+328.3% YoY
|
106.03M
66.90M – 147.59M
+106.5% YoY
|
| SGA |
28.75M
est: 8.07M (+256.5%)
|
91.14M
est: 31.47M (+189.6%)
|
38.56M
30.21M – 47.55M
+22.5% YoY
|
122.63M
88.88M – 144.79M
+218.0% YoY
|
249.63M
247.21M – 252.05M
+103.6% YoY
|
447.95M
320.79M – 583.00M
+79.4% YoY
|
593.94M
425.34M – 773.01M
+32.6% YoY
|
| EPS |
-2.34
est: -2.68 (+12.6%)
|
-2.85
est: -2.55 (-11.8%)
|
-4.04
-4.96 – -2.99
-58.6% YoY
|
-2.74
-3.35 – -2.31
+32.3% YoY
|
-0.80
-1.94 – 0.96
+70.7% YoY
|
1.78
1.12 – 2.48
+322.4% YoY
|
3.68
2.32 – 5.12
+106.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-21 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-87.08M
OE per share TTM
-2.85
Owner's Yield
-27.80%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
12.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
29
Total invested
39.66M
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VI, L.P. | 14.71M | 26.30% | 14.71M | — | 14.71M | 11.00 | PN | — | 2021-07-09 | ↗ |
| 2 | Samsara BioCapital, L.P. | 7.39M | 12.70% | — | 7.39M | — | 7.39M | PN | Delaware | 2021-07-09 | ↗ |
| 3 | EcoR1 Capital, LLC | 5.71M | 11.00% | — | 5.71M | — | 5.71M | IA, OO | Delaware | 2022-11-18 | ↗ |
| 4 | Oleg Nodelman | 5.71M | 11.00% | — | 5.71M | — | 5.71M | HC, IN | Delaware | 2022-11-18 | ↗ |
| 5 | EcoR1 Capital Fund Qualified, L.P. | 5.37M | 11.00% | — | 5.37M | — | — | PN | Delaware | 2022-11-18 | ↗ |
| 6 | Kolchinsky | 4.25M | 16.60% | — | 4.25M | — | 10.00 | HC, IN | United States | 2024-03-28 | ↗ |
| 7 | RA Capital Management, L.P. | 4.25M | 16.60% | — | 4.25M | — | 10.00 | IA, PN | Delaware | 2024-03-28 | ↗ |
| 8 | Rajeev Shah | 4.25M | 16.60% | — | 4.25M | — | 10.00 | HC, IN | United States | 2024-03-28 | ↗ |
| 9 | Alpha Wave Global, LP | 3.61M | 14.10% | — | 3.61M | — | — | IA | Delaware | 2024-03-28 | ↗ |
| 10 | Alpha Wave Ventures GP, Ltd | 3.61M | 14.10% | — | 3.61M | — | — | OO | Delaware | 2024-03-28 | ↗ |
| 11 | Chimera Investment LLC | 3.61M | 14.10% | — | 3.61M | — | — | OO | Delaware | 2024-03-28 | ↗ |
| 12 | Lunate Holding RSC LTD | 3.61M | 14.10% | — | 3.61M | — | — | OO | Delaware | 2024-03-28 | ↗ |
| 13 | Matthew Porteus | 3.53M | 6.10% | 3.53M | — | 3.53M | — | IN | — | 2022-02-14 | ↗ |
| 14 | RA Capital Healthcare Fund, L.P. | 3.37M | 13.20% | — | 3.37M | — | 10.00 | PN | Delaware | 2024-03-28 | ↗ |
| 15 | Ridgeback Capital Investments L.P. 66-0677421 | 1.95M | 7.20% | — | 1.95M | — | 1.95M | OO | Delaware | 2024-07-29 | ↗ |
| 16 | Ridgeback Capital Investments LLC 72-1614961 | 1.95M | 7.20% | — | 1.95M | — | 1.95M | OO | Delaware | 2024-07-29 | ↗ |
| 17 | Ridgeback Capital Management LLC 42-1684320 | 1.95M | 7.20% | — | 1.95M | — | 1.95M | OO | Delaware | 2024-07-29 | ↗ |
| 18 | Steven A. Cohen | 1.88M | 7.40% | — | 1.88M | — | — | IN | United States | 2024-03-25 | ↗ |
| 19 | GP-GP, | 1.71M | 3.10% | — | 1.71M | — | 11.00 | OO | — | 2021-07-09 | ↗ |
| 20 | L.P. | 1.71M | 3.10% | 1.71M | — | 1.71M | 11.00 | PN | — | 2021-07-09 | ↗ |
| 21 | 72 Investment Holdings, LLC | 1.02M | 4.00% | — | 1.02M | — | — | OO | Delaware | 2024-03-25 | ↗ |
| 22 | Differentiated Ventures Investments, LLC | 1.02M | 4.00% | — | 1.02M | — | — | OO | Delaware | 2024-03-25 | ↗ |
| 23 | Point72 Biotech Private Investments, LLC | 1.02M | 4.00% | — | 1.02M | — | — | OO | Delaware | 2024-03-25 | ↗ |
| 24 | Point72 Asset Management, L.P. | 864.9K | 3.40% | — | 864.9K | — | — | PN | Delaware | 2024-03-25 | ↗ |
| 25 | Point72 Capital Advisors, Inc. | 864.9K | 3.40% | — | 864.9K | — | — | CO | Delaware | 2024-03-25 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
29
-138 vs prev Q
New positions
8
Closed positions
140
Increased
20
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 398.6K +398.6K (+100.0%) | 6.38B +6.4B (+100.0%) | 1.40% +1.397 pp | 0.01% +0.010 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 2 | — | 78.8K +78.8K (+100.0%) | 1.26B +1.3B (+100.0%) | 0.28% +0.276 pp | 0.50% +0.498 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 4.18M +— (+0.0%) | 66.86M -127.8M (-65.7%) | 14.64% -0.241 pp | 0.69% -1.714 pp | USD21.01 -23.8% | 8 qtrs — |
| 4 | FMR LLC | 3.70M +3.6M (+4,140.7%) | 59.24M +55.2M (+1,356.7%) | 12.97% +12.663 pp | 0.00% +0.003 pp | USD16.26 -1.6% | 8 qtrs — |
| 5 | ALPHA WAVE GLOBAL, LP | 3.61M +— (+0.0%) | 57.80M -110.5M (-65.7%) | 12.66% -0.208 pp | 7.09% -9.956 pp | USD21.01 -23.8% | 8 qtrs — |
| 6 | VERSANT VENTURE MANAGEMENT, LLC | 2.66M +— (+0.0%) | 42.51M -81.2M (-65.7%) | 9.31% -0.153 pp | 28.14% -30.111 pp | USD46.58 -65.7% | 2 qtrs — |
| 7 | BLACKROCK, INC. | 1.69M +218.9K (+14.9%) | 27.07M -41.5M (-60.5%) | 5.93% +0.682 pp | 0.00% -0.001 pp | USD24.86 -35.6% | 6 qtrs — |
| 8 | UBS GROUP AG | 1.57M +370.1K (+30.8%) | 25.15M -30.8M (-55.1%) | 5.51% +1.228 pp | 0.00% -0.005 pp | USD28.31 -43.5% | 8 qtrs — |
| 9 | VANGUARD GROUP INC | 1.32M -9.1K (-0.7%) | 21.14M -40.8M (-65.9%) | 4.63% -0.108 pp | 0.00% -0.001 pp | USD21.23 -24.6% | 8 qtrs — |
| 10 | FRANKLIN RESOURCES INC | 1.10M +509.3K (+86.7%) | 17.54M -9.8M (-35.9%) | 3.84% +1.751 pp | 0.00% -0.003 pp | USD32.21 -50.3% | 4 qtrs — |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.02M +772.4K (+307.6%) | 16.38M +4.7M (+40.0%) | 3.59% +2.692 pp | 0.00% +0.001 pp | USD23.20 -31.0% | 6 qtrs — |
| 12 | 72 INVESTMENT HOLDINGS, LLC | 1.02M +— (+0.0%) | 16.28M -31.1M (-65.7%) | 3.57% -0.059 pp | 32.20% -37.572 pp | USD21.01 -23.8% | 8 qtrs — |
| 13 | TANG CAPITAL MANAGEMENT LLC | 865.2K -32.4K (-3.6%) | 13.84M -28.0M (-66.9%) | 3.03% -0.165 pp | 0.68% -0.926 pp | USD21.54 -25.7% | 8 qtrs — |
| 14 | INTRINSIC EDGE CAPITAL MANAGEMENT LLC | 569.7K +569.7K (+100.0%) | 9.12M +9.1M (+100.0%) | 2.00% +1.996 pp | 1.62% +1.625 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 15 | MILLENNIUM MANAGEMENT LLC | 539.3K +539.3K (+100.0%) | 8.63M +8.6M (+100.0%) | 1.89% +1.890 pp | 0.00% +0.004 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 16 | STATE STREET CORP | 510.7K +92.8K (+22.2%) | 8.17M -11.3M (-58.0%) | 1.79% +0.301 pp | 0.00% 0.000 pp | USD24.95 -35.9% | 8 qtrs — |
| 17 | C WORLDWIDE GROUP HOLDING A/S | 500.0K +500.0K (+100.0%) | 8.00M +8.0M (+100.0%) | 1.75% +1.752 pp | 0.14% +0.140 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 18 | SQUAREPOINT OPS LLC | 491.9K +402.1K (+447.8%) | 7.87M +3.7M (+88.2%) | 1.72% +1.404 pp | 0.01% +0.004 pp | USD21.16 -24.4% | 7 qtrs — |
| 19 | ABRDN PLC | 489.4K +358.7K (+274.4%) | 7.83M +1.7M (+28.6%) | 1.71% +1.249 pp | 0.01% +0.003 pp | USD21.55 -25.8% | 3 qtrs — |
| 20 | ALYESKA INVESTMENT GROUP, L.P. | 463.5K +221.4K (+91.4%) | 7.42M -3.9M (-34.2%) | 1.62% +0.762 pp | 0.02% -0.013 pp | USD21.35 -25.1% | 8 qtrs — |
| 21 | GEODE CAPITAL MANAGEMENT, LLC | 461.1K +6.2K (+1.4%) | 7.38M -13.8M (-65.2%) | 1.62% -0.005 pp | 0.00% -0.001 pp | USD22.55 -29.0% | 8 qtrs — |
| 22 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 431.1K +239.7K (+125.2%) | 6.90M -2.0M (-22.6%) | 1.51% +0.829 pp | 0.30% -0.070 pp | USD21.14 -24.3% | 5 qtrs — |
| 23 | CANDRIAM S.C.A. | 374.9K +146.0K (+63.8%) | 6.00M -4.7M (-43.7%) | 1.31% +0.498 pp | 0.03% -0.026 pp | USD26.78 -40.3% | 3 qtrs — |
| 24 | PRIMECAP MANAGEMENT CO/CA/ | 372.2K +372.2K (+100.0%) | 5.96M +6.0M (+100.0%) | 1.30% +1.304 pp | 0.00% +0.005 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 25 | TWO SIGMA INVESTMENTS, LP | 293.4K +233.3K (+387.6%) | 4.70M +1.9M (+67.5%) | 1.03% +0.814 pp | 0.01% +0.002 pp | USD22.27 -28.2% | 7 qtrs — |
| 26 | VESTAL POINT CAPITAL, LP | 275.0K +275.0K (+100.0%) | 4.40M +4.4M (+100.0%) | 0.96% +0.964 pp | 0.15% +0.150 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 27 | JACOBS LEVY EQUITY MANAGEMENT, INC | 270.9K +270.9K (+100.0%) | 4.33M +4.3M (+100.0%) | 0.95% +0.949 pp | 0.02% +0.017 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 28 | GOLDMAN SACHS GROUP INC | 257.9K +216.7K (+524.9%) | 4.13M +2.2M (+114.7%) | 0.90% +0.757 pp | 0.00% +0.000 pp | USD20.89 -23.4% | 7 qtrs — |
| 29 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 257.5K +21.2K (+9.0%) | 4.12M -6.9M (-62.6%) | 0.90% +0.061 pp | 0.21% -0.432 pp | USD37.62 -57.5% | 5 qtrs — |
| 30 | DISCOVERY CAPITAL MANAGEMENT, LLC / CT | 241.3K +241.3K (+100.0%) | 3.86M +3.9M (+100.0%) | 0.85% +0.846 pp | 0.21% +0.209 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 31 | MORGAN STANLEY | 233.4K -62.8K (-21.2%) | 3.73M -10.1M (-72.9%) | 0.82% -0.237 pp | 0.00% -0.001 pp | USD27.80 -42.4% | 8 qtrs — |
| 32 | PLUSTICK MANAGEMENT LLC | 200.0K +— (+0.0%) | 3.20M -6.1M (-65.7%) | 0.70% -0.012 pp | 1.42% -2.491 pp | USD46.58 -65.7% | 2 qtrs — |
| 33 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 185.6K +— (+0.0%) | 2.97M -5.7M (-65.7%) | 0.65% -0.011 pp | 0.01% -0.023 pp | USD37.90 -57.8% | 3 qtrs — |
| 34 | SOVRAN ADVISORS, LLC | 160.1K +53.2K (+49.8%) | 2.90M -352.0K (-10.8%) | 0.56% +0.180 pp | 0.25% -0.041 pp | USD32.06 -50.1% | 3 qtrs — |
| 35 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 174.7K +174.7K (+100.0%) | 2.80M +2.8M (+100.0%) | 0.61% +0.612 pp | 0.02% +0.019 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 36 | TREXQUANT INVESTMENT LP | 173.2K +173.2K (+100.0%) | 2.77M +2.8M (+100.0%) | 0.61% +0.607 pp | 0.02% +0.025 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 37 | HRT FINANCIAL LP | 171.3K +142.0K (+484.4%) | 2.74M +1.4M (+100.7%) | 0.60% +0.496 pp | 0.01% +0.004 pp | USD21.23 -24.6% | 2 qtrs — |
| 38 | PRELUDE CAPITAL MANAGEMENT, LLC | 170.2K +170.2K (+100.0%) | 2.72M +2.7M (+100.0%) | 0.60% +0.596 pp | 0.20% +0.200 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 39 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 169.1K +8.6K (+5.4%) | 2.71M -4.8M (-63.8%) | 0.59% +0.021 pp | 0.00% -0.001 pp | USD25.32 -36.8% | 8 qtrs — |
| 40 | NORTHERN TRUST CORP | 161.9K -3.4K (-2.0%) | 2.59M -5.1M (-66.4%) | 0.57% -0.021 pp | 0.00% -0.001 pp | USD22.92 -30.2% | 8 qtrs — |
| 41 | BLUE OWL CAPITAL HOLDINGS LP | 150.0K +150.0K (+100.0%) | 2.40M +2.4M (+100.0%) | 0.53% +0.526 pp | 0.18% +0.180 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 42 | AWM INVESTMENT COMPANY, INC. | 150.0K +150.0K (+100.0%) | 2.40M +2.4M (+100.0%) | 0.53% +0.526 pp | 0.23% +0.232 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 43 | AMERIPRISE FINANCIAL INC | 136.9K +81.2K (+145.9%) | 2.19M -402.9K (-15.5%) | 0.48% +0.281 pp | 0.00% 0.000 pp | USD19.65 -18.6% | 6 qtrs — |
| 44 | SCOGGIN MANAGEMENT LP | 125.0K -100.0K (-44.4%) | 2.00M -8.5M (-80.9%) | 0.44% -0.363 pp | 0.31% -1.333 pp | USD29.63 -46.0% | 4 qtrs — |
| 45 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 122.8K +23.4K (+23.5%) | 1.96M -2.7M (-57.6%) | 0.43% +0.076 pp | 0.00% 0.000 pp | USD40.75 -60.7% | 2 qtrs — |
| 46 | BANK OF AMERICA CORP /DE/ | 114.7K -234.4K (-67.2%) | 1.84M -14.4M (-88.7%) | 0.40% -0.842 pp | 0.00% -0.001 pp | USD42.93 -62.7% | 8 qtrs — |
| 47 | DIMENSIONAL FUND ADVISORS LP | 113.1K +72.2K (+176.6%) | 1.81M -91.2K (-4.8%) | 0.40% +0.251 pp | 0.00% +0.000 pp | USD17.77 -10.0% | 8 qtrs — |
| 48 | WOODLINE PARTNERS LP | 100.0K +100.0K (+100.0%) | 1.60M +1.6M (+100.0%) | 0.35% +0.350 pp | 0.01% +0.006 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 49 | AFFINITY ASSET ADVISORS, LLC | 100.0K +100.0K (+100.0%) | 1.60M +1.6M (+100.0%) | 0.35% +0.350 pp | 0.09% +0.091 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 50 | NOMURA ASSET MANAGEMENT CO LTD | 96.8K +53.0K (+121.1%) | 1.55M -490.5K (-24.1%) | 0.34% +0.183 pp | 0.00% -0.001 pp | USD29.83 -46.4% | 2 qtrs — |
| 51 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 83.2K -122.0 (-0.1%) | 1.40M -2.5M (-64.2%) | 0.29% -0.005 pp | 0.00% -0.004 pp | USD17.74 -9.8% | 7 qtrs — |
| 52 | XTX TOPCO LTD | 85.8K +85.8K (+100.0%) | 1.37M +1.4M (+100.0%) | 0.30% +0.301 pp | 0.04% +0.036 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 53 | TWO SIGMA ADVISERS, LP | 77.4K +69.7K (+905.9%) | 1.24M +880.3K (+245.5%) | 0.27% +0.244 pp | 0.00% +0.002 pp | USD19.04 -16.0% | 2 qtrs — |
| 54 | ENSIGN PEAK ADVISORS, INC | 77.3K +— (+0.0%) | 1.24M -2.4M (-65.7%) | 0.27% -0.004 pp | 0.00% -0.004 pp | USD25.71 -37.8% | 4 qtrs — |
| 55 | ALGERT GLOBAL LLC | 76.0K +76.0K (+100.0%) | 1.22M +1.2M (+100.0%) | 0.27% +0.266 pp | 0.02% +0.019 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 56 | BARCLAYS PLC | 72.4K +56.0K (+340.0%) | 1.16M +768.1K (+196.5%) | 0.25% +0.195 pp | 0.00% +0.000 pp | USD18.58 -13.9% | 8 qtrs — |
| 57 | VIVALDI CAPITAL MANAGEMENT LP | 64.1K +12.3K (+23.8%) | 1.02M -1.4M (-57.5%) | 0.22% +0.040 pp | 0.14% -0.201 pp | USD20.24 -20.9% | 8 qtrs — |
| 58 | FEDERATED HERMES, INC. | 62.6K +62.6K (+100.0%) | 1.00M +1.0M (+100.0%) | 0.22% +0.220 pp | 0.00% +0.002 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 59 | PROPEL BIO MANAGEMENT, LLC | 59.1K +59.1K (+100.0%) | 945.4K +945.4K (+100.0%) | 0.21% +0.207 pp | 0.81% +0.807 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 60 | WELLINGTON MANAGEMENT GROUP LLP | 54.4K -6.9K (-11.3%) | 870.4K -2.0M (-69.5%) | 0.19% -0.028 pp | 0.00% 0.000 pp | USD34.38 -53.5% | 6 qtrs — |
| 61 | KNOTT DAVID M JR | 53.7K -28.3K (-34.5%) | 859.7K -3.0M (-77.5%) | 0.19% -0.104 pp | 0.40% -1.142 pp | USD29.31 -45.4% | 3 qtrs — |
| 62 | PERCEPTIVE ADVISORS LLC | 50.0K +50.0K (+100.0%) | 800.0K +800.0K (+100.0%) | 0.18% +0.175 pp | 0.01% +0.014 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 63 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 48.1K +30.1K (+167.1%) | 769.1K -69.3K (-8.3%) | 0.17% +0.104 pp | 0.00% 0.000 pp | USD19.64 -18.5% | 4 qtrs — |
| 64 | VERITION FUND MANAGEMENT LLC | 46.3K +46.3K (+100.0%) | 740.3K +740.3K (+100.0%) | 0.16% +0.162 pp | 0.00% +0.003 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 65 | QUBE RESEARCH & TECHNOLOGIES LTD | 44.3K +44.3K (+100.0%) | 708.6K +708.6K (+100.0%) | 0.16% +0.155 pp | 0.00% +0.001 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 66 | BANK OF NEW YORK MELLON CORP | 44.1K -767.0 (-1.7%) | 704.9K -1.4M (-66.2%) | 0.15% -0.005 pp | 0.00% 0.000 pp | USD22.80 -29.8% | 8 qtrs — |
| 67 | ROYAL BANK OF CANADA | 43.2K -5.1K (-10.6%) | 691.0K -1.6M (-69.3%) | 0.15% -0.021 pp | 0.00% 0.000 pp | USD36.73 -56.4% | 8 qtrs — |
| 68 | AQUATIC CAPITAL MANAGEMENT LLC | 42.7K +42.7K (+100.0%) | 683.7K +683.7K (+100.0%) | 0.15% +0.150 pp | 0.02% +0.019 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 69 | SECTORAL ASSET MANAGEMENT INC | 42.5K +42.5K (+100.0%) | 680.0K +680.0K (+100.0%) | 0.15% +0.149 pp | 0.55% +0.545 pp | USD16.00 +0.0% | 8 qtrs — |
| 70 | JUMP FINANCIAL, LLC | 40.9K +40.9K (+100.0%) | 653.6K +653.6K (+100.0%) | 0.14% +0.143 pp | 0.01% +0.008 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 71 | Y-INTERCEPT (HONG KONG) LTD | 40.6K +40.6K (+100.0%) | 649.8K +649.8K (+100.0%) | 0.14% +0.142 pp | 0.01% +0.015 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 72 | NUVEEN, LLC | 39.9K -245.6K (-86.0%) | 638.5K -12.7M (-95.2%) | 0.14% -0.877 pp | 0.00% -0.003 pp | USD34.96 -54.2% | 4 qtrs — |
| 73 | VIRTUS INVESTMENT ADVISERS, INC. | 37.7K +33.8K (+879.3%) | 602.8K +423.6K (+236.4%) | 0.13% +0.118 pp | 0.16% +0.113 pp | USD17.36 -7.8% | 4 qtrs — |
| 74 | MARSHALL WACE, LLP | 35.3K +35.3K (+100.0%) | 564.0K +564.0K (+100.0%) | 0.12% +0.124 pp | 0.00% +0.001 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 75 | STATE OF WISCONSIN INVESTMENT BOARD | 32.2K +8.1K (+33.7%) | 515.8K -607.4K (-54.1%) | 0.11% +0.027 pp | 0.00% -0.001 pp | USD38.87 -58.8% | 2 qtrs — |
| 76 | ENGINEERS GATE MANAGER LP | 31.1K +31.1K (+100.0%) | 496.9K +496.9K (+100.0%) | 0.11% +0.109 pp | 0.01% +0.006 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 77 | KESTRA PRIVATE WEALTH SERVICES, LLC | 27.3K +— (+0.0%) | 436.9K -835.0K (-65.7%) | 0.10% -0.002 pp | 0.01% -0.011 pp | USD23.74 -32.6% | 6 qtrs — |
| 78 | TD ASSET MANAGEMENT INC | 27.0K -4.4K (-14.1%) | 431.6K -1.0M (-70.5%) | 0.09% -0.017 pp | 0.00% -0.001 pp | USD46.58 -65.7% | 6 qtrs — |
| 79 | HARBOR CAPITAL ADVISORS, INC. | 23.9K +9.3K (+63.8%) | 383.0K -297.0K (-43.7%) | 0.08% +0.032 pp | 0.03% -0.023 pp | USD23.69 -32.5% | 5 qtrs — |
| 80 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 23.1K +23.1K (+100.0%) | 370.4K +370.4K (+100.0%) | 0.08% +0.081 pp | 0.00% +0.003 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 81 | FREESTONE GROVE PARTNERS LP | 23.0K +23.0K (+100.0%) | 367.5K +367.5K (+100.0%) | 0.08% +0.081 pp | 0.00% +0.003 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 82 | WELLS FARGO & COMPANY/MN | 22.9K +12.5K (+119.3%) | 366.7K -120.0K (-24.7%) | 0.08% +0.043 pp | 0.00% +0.000 pp | USD20.13 -20.5% | 8 qtrs — |
| 83 | SWISS NATIONAL BANK | 21.8K +— (+0.0%) | 348.8K -666.6K (-65.7%) | 0.08% -0.001 pp | 0.00% 0.000 pp | USD28.93 -44.7% | 5 qtrs — |
| 84 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 20.8K -172.0 (-0.8%) | 334.9K -642.7K (-65.7%) | 0.07% -0.002 pp | 0.00% -0.001 pp | USD46.58 -65.7% | 6 qtrs — |
| 85 | RHUMBLINE ADVISERS | 20.3K -4.8K (-19.1%) | 324.0K -841.4K (-72.2%) | 0.07% -0.018 pp | 0.00% -0.001 pp | USD22.67 -29.4% | 8 qtrs — |
| 86 | CITADEL ADVISORS LLC | 19.9K +5.5K (+38.2%) | 318.4K -352.4K (-52.5%) | 0.07% +0.018 pp | 0.00% 0.000 pp | USD38.13 -58.0% | 2 qtrs — |
| 87 | AXQ CAPITAL, LP | 19.8K +14.7K (+289.2%) | 317.4K +80.0K (+33.7%) | 0.07% +0.051 pp | 0.07% -0.019 pp | USD23.86 -32.9% | 2 qtrs — |
| 88 | QUEST PARTNERS LLC | 19.6K +5.2K (+36.3%) | 313.8K -356.5K (-53.2%) | 0.07% +0.018 pp | 0.02% -0.026 pp | USD28.24 -43.3% | 4 qtrs — |
| 89 | JANE STREET GROUP, LLC | 19.6K +13.9K (+243.9%) | 313.6K +48.1K (+18.1%) | 0.07% +0.048 pp | 0.00% +0.000 pp | USD19.87 -19.5% | 3 qtrs — |
| 90 | DNB ASSET MANAGEMENT AS | 19.2K +19.2K (+100.0%) | 306.6K +306.6K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.001 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 91 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 19.2K +19.2K (+100.0%) | 306.0K +306.0K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.003 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 92 | UBS ASSET MANAGEMENT AMERICAS INC | 18.9K +7.2K (+61.2%) | 301.6K -243.2K (-44.6%) | 0.07% +0.024 pp | 0.00% 0.000 pp | USD24.26 -34.0% | 3 qtrs — |
| 93 | SIMPLIFY ASSET MANAGEMENT INC. | 17.5K +17.5K (+100.0%) | 279.7K +279.7K (+100.0%) | 0.06% +0.061 pp | 0.00% +0.005 pp | USD16.00 +0.0% | 1 qtrs NEW |
| 94 | KELLEHER FINANCIAL ADVISORS | 17.0K +— (+0.0%) | 272.4K -520.6K (-65.7%) | 0.06% -0.001 pp | 0.06% -0.136 pp | USD23.74 -32.6% | 6 qtrs — |
| 95 | QUANTBOT TECHNOLOGIES LP | 16.9K +16.9K (+100.0%) | 270.1K +270.1K (+100.0%) | 0.06% +0.059 pp | 0.01% +0.009 pp | USD16.00 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 51 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Harbor Human Capital Factor US Small Cap ETF HAPS | 0.05% | 91.1K | 0.61% |
| 2 | iShares Micro-Cap ETF IWC | 0.03% | 385.4K | 0.60% |
| 3 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.01% | 9.0K | 0.35% |
| 4 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.01% | 133.9K | 0.35% |
| 5 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.01% | 55.8K | 0.40% |
| 6 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.01% | 9.0K | 0.19% |
| 7 | iShares Biotechnology ETF IBB | 0.01% | 1.10M | 0.44% |
| 8 | Fidelity Enhanced Small Cap ETF FESM | 0.01% | 520.2K | 0.28% |
| 9 | Warren Street Global Equity ETF WSGE | 0.01% | 4.8K | 0.80% |
| 10 | Vanguard Russell 2000 Growth ETF VTWG | 0.01% | 143.8K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.33
Neutral
Ratio by volume
1.13
Neutral
Buys
4
Sells
3
Shares acquired
22.7K
Shares disposed
20.0K
Cash buys
3.00
Cash sales
2.00
Net activity
+2,698
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-27 | Schimmelpennink Evert B. | Director / Officer | P-Purchase | A | Common Stock | 28,089 | 8.95 | 251.4K | 77,289 | D | ↗ |
| 2026-03-27 | George Jeffrey P. | Director | P-Purchase | A | Common Stock | 5,592 | 8.92 | 49.9K | 5,592 | D | ↗ |
| 2026-03-27 | Chevallard Daniel R. | Officer | P-Purchase | A | Common Stock | 7,500 | 8.57 | 64.3K | 12,886 | D | ↗ |
| 2026-01-02 | Schimmelpennink Evert B. | Director / Officer | A-Award | A | Stock Option (right to buy) | 358,100 | 16.00 | 5.73M | 358,100 | D | ↗ |
| 2026-01-02 | Olsson Shawn | Officer | A-Award | A | Stock Option (right to buy) | 84,200 | 16.00 | 1.35M | 84,200 | D | ↗ |
| 2026-01-02 | Odrich Marc | Officer | A-Award | A | Stock Option (right to buy) | 84,200 | 16.00 | 1.35M | 84,200 | D | ↗ |
| 2026-01-02 | Chevallard Daniel R. | Officer | A-Award | A | Stock Option (right to buy) | 84,200 | 16.00 | 1.35M | 84,200 | D | ↗ |
| 2025-11-17 | Olsson Shawn | Officer | M-Exempt | A | Common Stock | 10,000 | 2.08 | 20.8K | 14,733 | D | ↗ |
| 2025-11-07 | MCCOLLUM JAMES W | Director | P-Purchase | A | Common Stock | 10,500 | 22.79 | 239.3K | 10,500 | D | ↗ |
| 2025-11-07 | Chevallard Daniel R. | Officer | P-Purchase | A | Common Stock | 2,178 | 22.76 | 49.6K | 5,386 | D | ↗ |
| 2025-09-30 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 49,701 | 45.35 | 2.25M | 1,133,842 | D | ↗ |
| 2025-09-18 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 268 | 43.30 | 11.6K | 1,183,543 | D | ↗ |
| 2025-08-26 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 43,978 | 38.97 | 1.71M | 1,277,662 | D | ↗ |
| 2025-08-25 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 50,270 | 39.53 | 1.99M | 1,323,789 | D | ↗ |
| 2025-08-22 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 20,493 | 40.03 | 820.3K | 1,379,727 | D | ↗ |
| 2025-08-18 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 15,085 | 38.56 | 581.7K | 962,878 | I | ↗ |
| 2025-08-15 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 145,051 | 39.50 | 5.73M | 1,430,848 | D | ↗ |
| 2025-07-10 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 191,376 | 34.00 | 6.51M | 1,575,899 | D | ↗ |
| 2025-06-27 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 200,000 | 30.47 | 6.09M | 1,767,275 | D | ↗ |
| 2025-06-20 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 133,924 | 30.25 | 4.05M | 1,967,275 | D | ↗ |
| 2025-06-18 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 100,000 | 29.95 | 3.00M | 1,148,789 | I | ↗ |
| 2025-06-11 | Thunen Shelley B | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 30.00 | 405.0K | 13,500 | D | ↗ |
| 2025-06-11 | Scheiner Zachary | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 30.00 | 405.0K | 13,500 | D | ↗ |
| 2025-06-11 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 13,500 | 30.00 | 405.0K | 13,500 | I | ↗ |
| 2025-06-11 | MCCOLLUM JAMES W | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 30.00 | 405.0K | 13,500 | D | ↗ |
| 2025-06-11 | Guerard Frederic | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 30.00 | 405.0K | 13,500 | D | ↗ |
| 2025-06-11 | George Jeffrey P. | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 30.00 | 405.0K | 13,500 | D | ↗ |
| 2025-06-11 | Drapkin Kimberlee C | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 30.00 | 405.0K | 13,500 | D | ↗ |
| 2025-06-10 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 350,000 | 29.00 | 10.15M | 1,248,789 | I | ↗ |
| 2025-04-09 | Olsson Shawn | Officer | M-Exempt | D | Stock Option (right to buy) | 1,400 | 2.08 | 2.9K | 63,241 | D | ↗ |
| 2025-03-07 | Schimmelpennink Evert B. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 4,200 | 1.04 | 4.4K | 337,906 | D | ↗ |
| 2025-01-09 | Schimmelpennink Evert B. | Director / Officer | A-Award | A | Stock Option (right to buy) | 279,100 | 26.34 | 7.35M | 279,100 | D | ↗ |
| 2025-01-09 | Olsson Shawn | Officer | A-Award | A | Stock Option (right to buy) | 80,100 | 26.34 | 2.11M | 80,100 | D | ↗ |
| 2025-01-09 | Odrich Marc | Officer | A-Award | A | Stock Option (right to buy) | 80,100 | 26.34 | 2.11M | 80,100 | D | ↗ |
| 2025-01-09 | Chevallard Daniel R. | Officer | A-Award | A | Stock Option (right to buy) | 70,444 | 26.34 | 1.86M | 70,444 | D | ↗ |
| 2024-12-16 | Olsson Shawn | Officer | M-Exempt | D | Stock Option (right to buy) | 3,333 | 2.08 | 6.9K | 64,641 | D | ↗ |
| 2024-07-22 | Schimmelpennink Evert B. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 45,000 | 1.04 | 46.8K | 342,106 | — | ↗ |
| 2024-05-14 | Chevallard Daniel R. | Officer | P-Purchase | A | Common Stock | 3,188 | 15.68 | 50.0K | 3,188 | — | ↗ |
| 2024-05-13 | MCCOLLUM JAMES W | Director | P-Purchase | A | Common Stock | 31,332 | 15.99 | 501.1K | 525,565 | — | ↗ |
| 2024-03-21 | Versant Venture Capital VII, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,598,789 | — | ↗ |
| 2024-03-21 | Versant Venture Capital VI, L.P. | 10% Owner | J-Other | A | Common Stock | 598,203 | 0.00 | — | 842,162 | — | ↗ |
| 2024-03-21 | Thunen Shelley B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-21 | Schimmelpennink Evert B. | Director / Officer | A-Award | A | Stock Option (right to buy) | 475,000 | 15.05 | 7.15M | 475,000 | — | ↗ |
| 2024-03-21 | Scheiner Zachary | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Warrants (Right to Buy) | 5,371 | 10.64 | 57.1K | 5,371 | — | ↗ |
| 2024-03-21 | Olsson Shawn | Officer | A-Award | A | Stock Option (right to buy) | 30,466 | 5.05 | 153.9K | 30,466 | — | ↗ |
| 2024-03-21 | Odrich Marc | Officer | A-Award | A | Stock Option (right to buy) | 66,472 | 6.04 | 401.5K | 66,472 | — | ↗ |
| 2024-03-21 | MCCOLLUM JAMES W | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-21 | Guerard Frederic | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-21 | George Jeffrey P. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-21 | Drapkin Kimberlee C | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 15.05 | 406.4K | 27,000 | — | ↗ |
| 2024-03-21 | Chevallard Daniel R. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-21 | Alpha Wave Ventures GP, Ltd | 10% Owner | — | I | Common Stock, par value $0.00001 per share | 0 | 0.00 | — | 3,612,211 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-151.9K
Shares Outstanding
31.35M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Evert Schimmelpennink President and Chief Executive Officer | 690.0K | — | — | 5.79M | 538.2K | 14.0K | 7.04M | 82.35% | ↗ |
| 2 | 2025 | Marc Odrich Chief Medical Officer | 500.0K | — | — | 1.66M | 260.0K | 14.0K | 2.44M | 68.24% | ↗ |
| 3 | 2025 | Shawn Olsson Chief Commercial Officer | 467.5K | — | — | 1.66M | 243.1K | 14.0K | 2.39M | 69.65% | ↗ |
| 4 | 2024 | Evert Schimmelpennink President and Chief Executive Officer | 607.1K | — | — | 5.91M | 450.5K | 13.8K | 6.98M | 84.66% | ↗ |
| 5 | 2024 | Marc Odrich Chief Medical Officer | 466.3K | — | — | 1.31M | 252.2K | 13.8K | 2.04M | 64.09% | ↗ |
| 6 | 2024 | Shawn Olsson Chief Commercial Officer | 412.7K | — | — | 1.31M | 225.2K | 13.8K | 1.96M | 66.73% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Evert Schimmelpennink | President, Chief Executive Officer, Secretary & Director | 1M | male |
| Marc G. Odrich | Chief Medical Officer | 774.0K | male |
| Shawn Olsson | Chief Commercial Officer | 724.6K | male |
| Daniel R. Chevallard | Chief Financial Officer | 680.4K | male |
| James W. McCollum | Co-Founder & Director | 40.0K | male |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | — | — |
| Domenick Porfidia | Vice President of Sales | — | male |
| Melissa Rosness | Senior Vice President of Manufacturing Operations | — | female |
| David Choromanski | Vice President of Marketing | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LENZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
